Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593381 | 0.91 | MAOA (0.56) | MAOAMAOBHTR2AIDO1SIGMAR1 | |
| SCHEMBL3592753 | 0.91 | MAOA (0.56) | MAOAMAOBHTR2AIDO1SIGMAR1 | |
| SCHEMBL3598070 | 0.91 | MAOA (0.56) | MAOAMAOBHTR2AIDO1SIGMAR1 | |
| SCHEMBL3581977 | 0.91 | MAOA (0.56) | MAOAMAOBHTR2AIDO1SIGMAR1 | |
| SCHEMBL3585702 | 0.91 | MAOA (0.56) | MAOAMAOBHTR2AIDO1SIGMAR1 | |
| SCHEMBL3590748 | 0.91 | MAOA (0.56) | MAOAMAOBHTR2AIDO1SIGMAR1 | |
| SCHEMBL3597857 | 0.91 | MAOA (0.56) | MAOAMAOBHTR2AIDO1SIGMAR1 | |
| SCHEMBL3584524 | 0.91 | MAOA (0.56) | MAOAMAOBHTR2AIDO1SIGMAR1 | |
| SCHEMBL3593459 | 0.91 | MAOA (0.56) | MAOAMAOBHTR2AIDO1SIGMAR1 | |
| SCHEMBL946179 | 0.85 | SMN1; SMN2 (0.52) | MAOAMAOBHTR2AIDO1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102365254-B | Method for producing alcohol compound | SUMITOMO CHEMICAL CO | 2014-08-27 | — | — | CN | disclosed |
| CN-102365254-A | Method for producing alcohol compound | SUMITOMO CHEMICAL CO | 2012-02-29 | — | — | CN | disclosed |
| US-7741242-B2 | Prepared by crosslinking a homogenized an addition polymer containing units from an unsaturated aryl-containing glycidyl ether or ester and an unsaturated alcohol or carboxylic acid and a zero-valent Pd compound to physically deposit the Pd compound on the polymer; oxidizing alcohols to aldehydes | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| EP-1537913-B1 | PALLADIUM CATALYST COMPOSITION | WAKO PURE CHEMICAL INDUSTIES L (JP) | 2009-07-01 | — | — | EP | disclosed |
| CN-101090723-A | Piperazine urea derivatives for the treatment of endometriosis | SCHERING AG (DE) | 2007-12-19 | — | — | CN | disclosed |
| CN-1938029-A | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma | UNIV PITTSBURGH (DE) | 2007-03-28 | — | — | CN | disclosed |
| CN-1838957-A | Chemokine inhibiting piperazine derivatives and their use to treat myocarditis | SCHERING AKTIEGESELLSCHAFT (DE) | 2006-09-27 | — | — | CN | disclosed |
| US-20060019822-A1 | Palladium catalyst composition | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1537913-A1 | PALLADIUM CATALYST COMPOSITION | Wako Pure Chemical Industies, Ltd. (JP) | 2005-06-08 | — | — | EP | disclosed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | disclosed |
| WO-2002018404-A9 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HOFFMANN LA ROCHE (CH) | 2003-10-02 | — | — | WO | disclosed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | disclosed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | MAOA 2989/4885MAOB 2340/4885HTR2A 3608/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | MAOA 2989/4885MAOB 2340/4885HTR2A 3608/4885 |
| US-20060019822-A1 | Palladium catalyst composition | ODC1, NUDC, ADH1C | MAOA 1512/4885MAOB 1581/4885HTR2A 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.